2 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 2 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Carboplatin plus Paclitaxel: new trials by email Literature Review of Carboplatin plus Paclitaxel trials Research Report on Carboplatin plus Paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 126 | 2025-05-22 | 2025-07-02 |
| Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed - Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | Immutep S.A.S. | 756 | 2025-03-21 | 2026-03-18 |
| A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel - Solid Tumor Cancer, Chemotherapy Induced Neutropenia | Not applicable | Not yet recruiting | Shandong Cancer Hospital and Institute | 200 | 2024-10-10 | 2024-10-18 |
| Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 18 | 2024-05-28 | 2025-07-02 |
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel - Carcinoma, Non-Small Cell Lung | Phase 3 | Terminated | Bayer | 926 | 2006-02-01 | 2014-11-04 |
Carcinoma, Non-Small-Cell Lung (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2)
The University of Hong Kong (2) · Bayer (1) · Immutep S.A.S. (1) · Shandong Cancer Hospital and Institute (1)
Hong Kong (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Chile (2) · China (2) · Germany (2) · Hungary (2) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · United States (2)
Ka Yu Tse, MBBS, MMedSc, PhD, FRCOG (2) · JinMing Yu, Phd (1)
2005 (1)